Emergent BioSolutions/$EBS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Emergent BioSolutions
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Ticker
$EBS
Sector
Primary listing
NYSE
Employees
900
Headquarters
Website
EBS Metrics
BasicAdvanced
$427M
3.17
$2.53
1.98
-
Price and volume
Market cap
$427M
Beta
1.98
52-week high
$11.98
52-week low
$4.02
Average daily volume
1.3M
Financial strength
Current ratio
5.661
Quick ratio
2.731
Long term debt to equity
124.543
Total debt to equity
126.091
Interest coverage (TTM)
2.25%
Profitability
EBITDA (TTM)
216.8
Gross margin (TTM)
56.39%
Net profit margin (TTM)
16.38%
Operating margin (TTM)
13.86%
Effective tax rate (TTM)
26.85%
Revenue per employee (TTM)
$950,000
Management effectiveness
Return on assets (TTM)
5.03%
Return on equity (TTM)
30.24%
Valuation
Price to earnings (TTM)
3.165
Price to revenue (TTM)
0.507
Price to book
0.8
Price to tangible book (TTM)
6.39
Price to free cash flow (TTM)
2.333
Free cash flow yield (TTM)
42.86%
Free cash flow per share (TTM)
3.429
Growth
Revenue change (TTM)
-22.74%
Earnings per share change (TTM)
-122.45%
3-year revenue growth (CAGR)
-18.63%
10-year revenue growth (CAGR)
6.42%
3-year earnings per share growth (CAGR)
14.39%
10-year earnings per share growth (CAGR)
9.78%
What the Analysts think about EBS
Analyst ratings (Buy, Hold, Sell) for Emergent BioSolutions stock.
Bulls say / Bears say
Emergent reported Q2 2025 Adjusted EBITDA of $28.5 million, a 382% increase versus Q2 2024, with the adjusted EBITDA margin expanding to 20%, reflecting substantial operational leverage improvements. (SEC)
Emergent sold its Baltimore-Bayview biologics facility to Syngene International for $36.5 million in March 2025, streamlining operations while retaining manufacturing collaboration rights, supporting focus on core biodefense and commercial products. (Reuters)
Emergent was added to the Russell 3000® Index effective June 27, 2025, enhancing visibility among institutional investors managing index-tracked assets and potentially broadening its shareholder base. (GlobeNewswire)
Total revenues for Q2 2025 declined 45% year-over-year to $140.9 million, reflecting significant top-line pressure from the loss of divested revenues and lower product sales. (SEC)
NARCAN Nasal Spray revenues fell 44% year-over-year to $67.5 million in Q2 2025, driven by weaker OTC demand and lower Canadian branded sales, challenging the stability of its core commercial segment. (GlobeNewswire)
Anthrax MCM product sales dropped 70% year-over-year to $11.6 million in Q2 2025 due to timing shifts in CYFENDUS and BioThrax purchase options, underscoring volatility in government contract-driven revenues. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
EBS Financial Performance
Revenues and expenses
EBS Earnings Performance
Company profitability
EBS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Emergent BioSolutions stock?
Emergent BioSolutions (EBS) has a market cap of $427M as of September 16, 2025.
What is the P/E ratio for Emergent BioSolutions stock?
The price to earnings (P/E) ratio for Emergent BioSolutions (EBS) stock is 3.17 as of September 16, 2025.
Does Emergent BioSolutions stock pay dividends?
No, Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Emergent BioSolutions dividend payment date?
Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders.
What is the beta indicator for Emergent BioSolutions?
Emergent BioSolutions (EBS) has a beta rating of 1.98. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.